Last update 19 Apr 2025

GB-268

Overview

Basic Info

Drug Type
Trispecific antibody, Polyclonal antibody
Synonyms
GB 268, GB268
Target
CTLA4 x PD-1 x VEGF
Action
inhibitors
Mechanism
CTLA4 inhibitors(Cytotoxic T-Lymphocyte-Associated Antigen 4 inhibitors), PD-1 inhibitors(Programmed cell death protein 1 inhibitors), VEGF inhibitors(Vascular endothelial growth factor inhibitors)
Therapeutic Areas
Neoplasms
Active Indication
Locally Advanced Malignant Solid NeoplasmNeoplasms
Inactive Indication-
Originator Organization
Genor Biopharma Co., Ltd.Genor Biopharma Co., Ltd.
Active Organization
Genor Biopharma Co., Ltd.Genor Biopharma Co., Ltd.
Inactive Organization-
Drug Highest PhasePhase 1
First Approval Date-
Regulation-
Login to view timeline

Related

1
Clinical Trials associated with GB-268
NCT06934616
/ Not yet recruitingPhase 1
A Phase I, First-in-Human, Open-Label, Multicenter Study Evaluating the Safety, Tolerability, Pharmacokinetics and Efficacy of a Trispecific PD-1/CTLA-4/ VEGF Antibody GB268 in Participants With Advanced Solid Tumors
100 Clinical Results associated with GB-268
Login to view more data
100 Translational Medicine associated with GB-268
Login to view more data
100 Patents (Medical) associated with GB-268
Login to view more data
100 Deals associated with GB-268
Login to view more data

R&D Status

10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
Locally Advanced Malignant Solid NeoplasmPhase 1-
Genor Biopharma Co., Ltd.Genor Biopharma Co., Ltd.
24 Apr 2025
NeoplasmsPreclinical
China
Genor Biopharma Co., Ltd.Genor Biopharma Co., Ltd.
30 Aug 2023
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date

No Data

Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
login
or
view full example data
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
login
or
view full example data
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
login
or
view full example data
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
login
or
view full example data
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
login
or
view full example data
Accelerate your research with the latest regulatory approval information.

Biosimilar

Competitive landscape of biosimilars in different countries/locations. Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3.
login
or
view full example data
Competitive landscape of biosimilars in different countries/locations. Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3.

Regulation

Understand key drug designations in just a few clicks with Synapse.
login
or
view full example data
Understand key drug designations in just a few clicks with Synapse.
Chat with Hiro
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free